442 related articles for article (PubMed ID: 21447798)
21. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
Van Schaeybroeck S; Kyula JN; Fenton A; Fenning CS; Sasazuki T; Shirasawa S; Longley DB; Johnston PG
Cancer Res; 2011 Feb; 71(3):1071-80. PubMed ID: 21148749
[TBL] [Abstract][Full Text] [Related]
23. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
[TBL] [Abstract][Full Text] [Related]
24. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
[TBL] [Abstract][Full Text] [Related]
25. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
26. MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
Gong J; Chen Y; Yang L; Pillai R; Shirasawa S; Fakih M
Anticancer Res; 2017 Jun; 37(6):2831-2838. PubMed ID: 28551618
[TBL] [Abstract][Full Text] [Related]
27. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim.
Meng J; Fang B; Liao Y; Chresta CM; Smith PD; Roth JA
PLoS One; 2010 Sep; 5(9):e13026. PubMed ID: 20885957
[TBL] [Abstract][Full Text] [Related]
29. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
Sale MJ; Cook SJ
Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
[TBL] [Abstract][Full Text] [Related]
30. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
31. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
Bass A
J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
[No Abstract] [Full Text] [Related]
32. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
33. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
34. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
[TBL] [Abstract][Full Text] [Related]
35. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.
Bid HK; Kibler A; Phelps DA; Manap S; Xiao L; Lin J; Capper D; Oswald D; Geier B; DeWire M; Smith PD; Kurmasheva RT; Mo X; Fernandez S; Houghton PJ
Clin Cancer Res; 2013 Dec; 19(24):6716-29. PubMed ID: 24132923
[TBL] [Abstract][Full Text] [Related]
36. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
37. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
Andrews MC; Behren A; Chionh F; Mariadason J; Vella LJ; Do H; Dobrovic A; Tebbutt N; Cebon J
J Clin Oncol; 2013 Dec; 31(35):e448-51. PubMed ID: 24190114
[No Abstract] [Full Text] [Related]
38. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
39. AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models.
Kim EY; Kim A; Kim SK; Chang YS
Cancer Lett; 2015 Mar; 358(1):85-91. PubMed ID: 25541062
[TBL] [Abstract][Full Text] [Related]
40. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
